News

13 June 2017

Novel SGLT-2 inhibitor boosts glycaemic control

Feedback View all current articles | Print Print this article | Feedback  Provide feedback

The investigational SGLT-2 inhibitor ertugliflozin improves glycaemic control in adults with type 2 diabetes, according to research presented at the American Diabetes Association Meeting in San Diego.

Medpage Today

Other stories that may interest you:

Recognising Success at ECE 2017 (26 Jun 2017)

ESE journal’s impact factor success (15 Jun 2017)

ESE journal’s impact factor success (15 Jun 2017)